Go-Less® Men has been clinically shown to improve urinary symptom frequency and severity in men with benign prostate hyperplasia (BPH)


The aim

The aim of the present study was to investigate the efficacy of the proprietary Go-Less® Men on lower urinary tract symptoms and quality of life in men with BPH, as well as to assess its tolerability.


Study Design

Sixty men suffering from moderate or severe symptomatic BPH participated in the study. They received 500 mg Go-Less® Men daily for 12 weeks. Change in IPSS within the treatment period was assessed. Frequency of nocturia was recorded by bladder diaries and post-void residual urine volume was determined via ultrasound.



Between baseline and after 12 weeks of supplementation a significant symptom reduction of on average 30.1% was seen for the total IPSS. Symptom alleviation had a high impact on the quality of life and was significant after 8 and 12 weeks of intervention. Nocturia significantly decreased over time, as confirmed by the IPSS questionnaire and bladder diary. Post-void residual urine volume was significantly reduced at the end of the intervention.

Figure 1. Total IPSS score (*** p < 0.001)

Total symptom score IPSS

The total symptom score IPSS was reduced by 30.1% on average, at the end of the supplementation period.

Figure 2. Nocturia (mean ±95% CI; ***P < 0.001, **P < .01)

Frequency of urination overnight

The effect on nocturia evidenced via IPSS was also confirmed by analyzing the participants’ bladder diaries.

Figure 3. Postvoid volume

Residual post void urine volume

Ultrasound examination further documented a significant drop of post-void urinary volume at the end of the intervention.



The study demonstrates the positive effects of Go-Less® Men after just 4 weeks of supplementation.

This response was shown to be further augmented over the remaining study period with no reported side effects.